Transcription of Press release Third quarter 2021
{{id}} {{{paragraph}}}
Example: air traffic controller
Press release Third quarter 2021
Press release Third quarter 2021 Q3 Results summary Total and Adjusted results Quarterly performance YTD performance Financial information Issued: Wednesday, 27 October 2021, London, 1 Issued: Wednesday, 27 October 2021, London GSK delivers strong Q3 sales of billion +5% AER, +10% CER Total EPS -7% AER, +3% CER; Adjusted EPS +3% AER, +10% CER 2021 full year EPS guidance improved Highlights Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand Pharmaceuticals billion +5% AER, +10% CER with growth in New and Specialty medicines +24% CER; Respiratory +33% CER; Immuno-inflammation +32% CER ex-COVID-19 solutions; Oncology +34% CER; total HIV +8% CER Vaccines billion +7% AER, +13% CER with Shingrix 502 million +41% CER COVID-19 solutions sales 209 million; Xevudy 114 million and pandemic adjuvant
Vaccines turnover grew 7% AER, 13% CER to £2,174 million, primarily driven by higher Shingrix sales in the US and Europe and pandemic adjuvant sales. Unfavourable US prior period returns and rebates adjustments reduced overall Vaccines growth by approximately 3 percentage points. Vaccines turnover excluding
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: